These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22249108)

  • 1. Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion.
    Shimada K; Motoi Y; Ishiguro K; Kambe T; Matsumoto SE; Itaya M; Kunichika M; Mori H; Shinohara A; Chiba M; Mizuno Y; Ueno T; Hattori N
    Neurobiol Dis; 2012 Apr; 46(1):101-8. PubMed ID: 22249108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.
    Leroy K; Ando K; Héraud C; Yilmaz Z; Authelet M; Boeynaems JM; Buée L; De Decker R; Brion JP
    J Alzheimers Dis; 2010; 19(2):705-19. PubMed ID: 20110614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies.
    Nakashima H; Ishihara T; Suguimoto P; Yokota O; Oshima E; Kugo A; Terada S; Hamamura T; Trojanowski JQ; Lee VM; Kuroda S
    Acta Neuropathol; 2005 Dec; 110(6):547-56. PubMed ID: 16228182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo.
    Noble W; Planel E; Zehr C; Olm V; Meyerson J; Suleman F; Gaynor K; Wang L; LaFrancois J; Feinstein B; Burns M; Krishnamurthy P; Wen Y; Bhat R; Lewis J; Dickson D; Duff K
    Proc Natl Acad Sci U S A; 2005 May; 102(19):6990-5. PubMed ID: 15867159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
    Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
    Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.
    Rodríguez-Navarro JA; Rodríguez L; Casarejos MJ; Solano RM; Gómez A; Perucho J; Cuervo AM; García de Yébenes J; Mena MA
    Neurobiol Dis; 2010 Sep; 39(3):423-38. PubMed ID: 20546895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice.
    Xu J; Sato S; Okuyama S; Swan RJ; Jacobsen MT; Strunk E; Ikezu T
    FASEB J; 2010 Aug; 24(8):2904-15. PubMed ID: 20354135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
    Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
    J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
    Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
    Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.
    Uno Y; Iwashita H; Tsukamoto T; Uchiyama N; Kawamoto T; Kori M; Nakanishi A
    Brain Res; 2009 Nov; 1296():148-63. PubMed ID: 19698704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of alpha-tocopherol on an animal model of tauopathies.
    Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S
    Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice.
    Frederick C; Ando K; Leroy K; Héraud C; Suain V; Buée L; Brion JP
    J Alzheimers Dis; 2015; 44(4):1145-56. PubMed ID: 25408212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
    Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
    Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.
    Lewis J; McGowan E; Rockwood J; Melrose H; Nacharaju P; Van Slegtenhorst M; Gwinn-Hardy K; Paul Murphy M; Baker M; Yu X; Duff K; Hardy J; Corral A; Lin WL; Yen SH; Dickson DW; Davies P; Hutton M
    Nat Genet; 2000 Aug; 25(4):402-5. PubMed ID: 10932182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model.
    Pérez M; Hernández F; Lim F; Díaz-Nido J; Avila J
    J Alzheimers Dis; 2003 Aug; 5(4):301-8. PubMed ID: 14624025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic lithium treatment up-regulates cell surface Na(V)1.7 sodium channels via inhibition of glycogen synthase kinase-3 in adrenal chromaffin cells: enhancement of Na(+) influx, Ca(2+) influx and catecholamine secretion after lithium withdrawal.
    Yanagita T; Maruta T; Nemoto T; Uezono Y; Matsuo K; Satoh S; Yoshikawa N; Kanai T; Kobayashi H; Wada A
    Neuropharmacology; 2009 Sep; 57(3):311-21. PubMed ID: 19486905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate.
    Bondulich MK; Guo T; Meehan C; Manion J; Rodriguez Martin T; Mitchell JC; Hortobagyi T; Yankova N; Stygelbout V; Brion JP; Noble W; Hanger DP
    Brain; 2016 Aug; 139(Pt 8):2290-306. PubMed ID: 27297240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium inhibits neurite growth and tau protein kinase I/glycogen synthase kinase-3beta-dependent phosphorylation of juvenile tau in cultured hippocampal neurons.
    Takahashi M; Yasutake K; Tomizawa K
    J Neurochem; 1999 Nov; 73(5):2073-83. PubMed ID: 10537067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated ultrasound treatment of tau transgenic mice clears neuronal tau by autophagy and improves behavioral functions.
    Pandit R; Leinenga G; Götz J
    Theranostics; 2019; 9(13):3754-3767. PubMed ID: 31281511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.